The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2022 | Identification of myeloma high-risk subclones with single-cell technologies
Jill Corre, PharmD, PhD, The Cancer University Institute of Toulouse Oncopole (IUCT), Toulouse, France, comments on the use of single-cell technologies to identify patients with high-risk subclones at diagnosis to better stratify patients into standard and high-risk categories and thus help prevent early relapse. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.
